Clinical Trial
Additional Information
The Web's Daily Resource for Alzheimer's News In the 04/11/2022 edition:
AL001 May Deliver Lithium’s Benefits for Dementia With Less Toxicity AL001 May Deliver Lithium’s Benefits for Dementia With Less Toxicity By Patricia Inacio PhD on 04/07/2022 lithium for dementia | Alzheimer's News Today | illustration of clinical trials charts.
Alzamend Neuro’s experimental oral therapy for dementia related to Alzheimer’s disease may deliver the benefits of marketed lithium-based treatments but with fewer side effects, data from a completed Phase 1 trial show. A 150 milligrams (mg) dose of the therapy, called AL001, led to similar levels of lithium in the blood as a 300 mg […] The post AL001 May Deliver Lithium’s Benefits for Dementia With Less Toxicity appeared first on Alzheimer's News Today.
Alzheimer's in the News
IGC Starts Phase 1 Study of Low-dose Cannabinoid in Alzheimer’s Patients NOVEMBER 30, 2020
A Phase 1 trial is enrolling patients with mild to severe dementia from Alzheimer’s disease to test IGC-AD1, an investigational cannabis-based treatment being developed India Globalization Capital (IGC) Pharma, a subsidiary of IGC, according to a recent press release.
UPDATE - FDA Committee Votes Do Not Support Aducanumab as Effective Treatment
An advisory arm of the U.S. Food and Drug Administration (FDA) is recommending that available clinical data on aducanumab (BIIB037) does not support the effectiveness of this investigational therapy in treating Alzheimer’s disease. (Alzheimer's News Today)
FDA Clears Neuraly to Begin Phase 2 Trial of NLY01 in Alzheimer’s Patients
The U.S. Food and Drug Administration has given clearance for a Phase 2B clinical trial to evaluate the safety, tolerability, and efficacy of Nueraly‘s investigational therapy NLY01 in people with Alzheimer’s disease. (Alzheimer's News Today)
Information About COVID-19 for Alzheimer’s Disease Patients
FDA Approval
Aducanumab, originally developed by Neurimmune and partnering with Biogen in 2007, was granted priority review by the FDA in August 2020, for treating Alzheimer's disease.
FDA Request for Comments on Aducanumab (Submit by Nov. 5, 2020)
On November 6, 2020, the committee will discuss biologics license application (BLA) 761178, for aducanumab solution for intravenous infusion, submitted by Biogen Inc., for the treatment of Alzheimer's disease. If you want to submit comments for the meeting, use this link:
FDA Request for Comments on Aducanumab (Submit by Nov. 5, 2020)
On November 6, 2020, the committee will discuss biologics license application (BLA) 761178, for aducanumab solution for intravenous infusion, submitted by Biogen Inc., for the treatment of Alzheimer's disease. If you want to submit comments for the meeting, use this link:
Can A Language Test Predict Alzheimer's Disease?
According to the journal The Lancet eClinicalMedicine. a language test has been discovered that can be combined with artificial intelligence to predict who will develop Alzheimer's disease later in life.
Don't Worry, Be Happy
I'm sure you've heard the term laughter is the best medicine, this is also true for Caregivers of persons living with Alzheimer's disease and other related dementias. Read more in this article by Ray Burrow, titled Treading Dark Waters.
Need Support from the Alzheimer's Association?
The Alzheimer's Association is here to help you! Use the 24/7 helpline for support of Caregivers and persons living with Alzheimer's disease. 1.800.272.3900. Click here for more information.
Need Support from the Alzheimer's Foundation?
The Alzheimer's Foundation is here to help you! Use the helpline for support of Caregivers and persons living with Alzheimer's disease. Click here for more information.
Promote current deals
The U.S. Food and Drug Administration has given clearance for a Phase 2B clinical trial to evaluate the safety, tolerability, and efficacy of Nueraly‘s investigational therapy NLY01 in people with Alzheimer’s disease.